Its probably not as dire as you have indicated. I dont think there isnt actual interest for Felix as the reason why continued buying hasnt occured. I think the more likely scenario is that MEM were optimistic in their prospects for market penetration. We're still waiting for the results for the Vitrolife Japan study, and whilst they did not require their version of TGA approval for the Felix product, I'm guessing the clinics are hesitant to take on the product without TGA or CE Mark before wide adoption.
It would be good to get a high-level director from a participating IVF clinic's perspective on this. The biggest concern I can see though is that they have families' babies literally in their hands, and maybe a little more cautious about their approach.
MEM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)